ExpreS2ion Biotech Holding AB announced the appointment of Dr. Mattis F. Ranthe as the Company's new Chief Medical Officer (CMO). Dr. Ranthe will begin his employment on February 1, 2022 at ExpreS2ion's headquarters in Hørsholm, Denmark. Dr. Mattis F. Ranthe will take over the responsibility for the Company's development pipeline activities from Dr. Lars J. Petersen, who will step down from his position as part-time Medical Director, Oncology, in light of the new CMO role. At ExpreS2ion, the Company's medical activities will continue to be supported by drug development consultants within oncology, which will now be under Mattis' leadership.